Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

A. S. Abeyagunawardena, D. Goldblatt, Nicholas Andrews, R. S. Trompeter

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

Original languageEnglish
Pages (from-to)449-450
Number of pages2
JournalThe Lancet
Volume362
Issue number9382
DOIs
Publication statusPublished - 9 Aug 2003

Fingerprint

Dive into the research topics of 'Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome'. Together they form a unique fingerprint.

Cite this